Efficacy of infliximab in a rabbit model of osteoarthritis.

Connect Tissue Res

Department of Rheumatology, Lishui Center Hospital, Lishui, PR China.

Published: June 2013

The purpose of this study was to investigate the efficacy of intra-articular injection of infliximab in a rabbit model of osteoarthritis. In 30 New Zealand white rabbits, the cruciate ligaments and medial menisci were resected using the Hulth technique. Eight weeks postsurgery, the animals were randomly divided into three groups, and each group was given monthly intra-articular injections (0.5 ml) of 10 mg/ml infliximab, 20 mg/ml infliximab, or saline, respectively. After 3 months, the results were assessed by macroscopic observation, histological evaluation, and measurement of the levels of interleukin-1β, tumor necrosis factor-α, and nitric oxide in the synovial fluid. In the two groups of rabbits administered infliximab (10 or 20 mg/ml), the pathological changes were more attenuated than in the group administered saline. Mankin scores in the rabbits administered infliximab 10 mg/ml (2.7 ± 0.9) or infliximab 20 mg/ml (2.4 ± 0.7) were significantly lower than in the control group (6.4 ± 1.2) (p <0.05). The tumor necrosis factor-α and nitric oxide contents of the synovial fluid were also decreased significantly in the rabbits administered infliximab at both concentrations compared with the saline-injected rabbits (p <0.05). Administration of infliximab did not change the levels of interleukin-1β in the synovial fluid. Similar results were obtained for all analyses with the two concentrations of infliximab tested. This study demonstrates that intra-articular injections of infliximab can protect against the development of experimentally induced osteoarthritis.

Download full-text PDF

Source
http://dx.doi.org/10.3109/03008207.2012.661001DOI Listing

Publication Analysis

Top Keywords

infliximab mg/ml
16
mg/ml infliximab
12
infliximab rabbit
8
rabbit model
8
model osteoarthritis
8
rabbits administered
8
administered infliximab
8
infliximab
6
mg/ml
5
efficacy infliximab
4

Similar Publications

Infliximab monitoring in Crohn's disease: a neural network approach for evaluating disease activity and immunogenicity.

Therap Adv Gastroenterol

May 2024

Inflammatory Bowel Disease Research Laboratory (LabDII), Gastrocenter, Colorectal Surgery Unit, Surgery Department, School of Medical Sciences, University of Campinas, Carlos Chagas Street, 420, Cidade Universitária Zeferino Vaz, Campinas 13083-878, São Paulo, Brazil.

Background: The treatment for Crohn's disease (CD) has increasingly required the use of biological agents. Safe and affordable tests have led to the active implementation of therapeutic drug monitoring (TDM) in clinical practice, which, although not yet widely available across all health services, has been proven effective.

Objective: To analyze serum infliximab (IFX) and antidrug antibody (ADA) levels in CD patients, compare two tests, as well as construct a prediction of neural network using a combination of clinical, epidemiological, and laboratory variables.

View Article and Find Full Text PDF

Objective: Subcutaneous (SC) infliximab (IFX) and vedolizumab (VDZ) have recently become available. We aimed to examine the impact of switching from intravenous (IV) to SC IFX and VDZ in patients with inflammatory bowel disease (IBD) on costs, the day hospital burden, trough levels, and clinical outcomes.

Methods: Our study comprised the cohort of IBD patients receiving IV IFX or VDZ at our hospital in 2022.

View Article and Find Full Text PDF

Ocrelizumab and ofatumumab, but not rituximab, trigger complement induction in vitro.

Int Immunopharmacol

November 2023

Section of Clinical Pharmacology, Department of Medical Biochemistry and Pharmacology, Haukeland University Hospital, Jonas Lies vei 87, N-5021 Bergen, Norway; Department of Clinical Science, University of Bergen, Jonas Lies vei 87, N-5021 Bergen, Norway. Electronic address:

Article Synopsis
  • The study investigates the clinical effects and adverse reactions of three therapeutic monoclonal antibodies (mAbs) used for treating multiple sclerosis (MS): ocrelizumab, ofatumumab, and rituximab.
  • Ocrelizumab and ofatumumab are approved for MS treatment, while rituximab is used off-label and is less expensive.
  • The research focused on comparing how these mAbs activate the complement system, which can lead to adverse infusion reactions, showing that ofatumumab and ocrelizumab significantly trigger complement activation, unlike rituximab and adalimumab.
View Article and Find Full Text PDF

Background: Switching from originator infliximab (IFX) to biosimilar IFX is effective and safe. However, data on multiple switching are scarce. The Edinburgh inflammatory bowel disease (IBD) unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021).

View Article and Find Full Text PDF

Degradation and in-use stability study of five marketed therapeutic monoclonal antibodies by generic weak cation exchange liquid chromatographic method ((WCX)HPLC/DAD).

J Chromatogr B Analyt Technol Biomed Life Sci

July 2022

Department of Analytical Chemistry, Science Faculty, University of Granada, Granada, Spain; Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, Spain. Electronic address:

Therapeutic monoclonal antibodies (mAbs) represent a very important class of the current biopharmaceutics. The great complexity of their structure made necessary the use of different analytical approaches for assessing different physico-chemical properties. In this work, weak cation exchange (WCX) high performance liquid chromatography with diode array detection ((WCX)HPLC/DAD) is used to assess the charge variant profile.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!